チロシンキナーゼ阻害剤の市場規模、シェア、成長分析：タイプ別、用途別、エンドユーザー別、流通チャネル別、地域別-産業予測、2025～2032年

世界のチロシンキナーゼ阻害剤の市場規模は2023年に369億米ドルと評価され、2024年の390億米ドルから2032年には607億7,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは5.7%で成長する見通しです。

チロシンキナーゼ阻害剤（TKI）市場は、これらの極めて重要な治療法を必要とするがんや慢性疾患の罹患率の上昇に後押しされ、力強い成長を遂げています。細胞シグナル伝達経路に関与する酵素を特異的に標的とするTKIは、肺がん、乳がん、白血病などの多様ながんを治療する個別化医療に不可欠です。最近の分子生物学と薬剤開発の動向は、より効果的で選択的なTKIの登場につながり、患者の予後を改善し、利用可能な治療法の幅を広げています。耐性に対抗し、副作用を軽減する次世代の阻害剤を目的とした活発な研究開発の取り組みにより、市場は活性化しています。しかし、高コストや規制上のハードルといった課題は依然として残っています。特に、免疫療法との併用療法や革新的なドラッグデリバリーシステムといった動向は、世界のヘルスケアインフラの成長とともに、市場の拡大をさらに促進すると期待されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次・一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

チロシンキナーゼ阻害剤市場規模：タイプ別、CAGR（2025～2032年）

• 市場概要
• BCR-ABLチロシンキナーゼ阻害剤
• 上皮成長因子受容体（EGFR）チロシンキナーゼ阻害剤
• 血管内皮成長因子（VEGFR）チロシンキナーゼ阻害剤
• その他

チロシンキナーゼ阻害剤市場規模：用途別、CAGR（2025～2032年）

• 市場概要
• 慢性骨髄性白血病（CML）
• 肺がん
• 乳がん
• その他

チロシンキナーゼ阻害剤市場規模：エンドユーザー別、CAGR（2025～2032年）

• 市場概要
• 病院
• ホームケア
• 専門クリニック
• その他

チロシンキナーゼ阻害剤市場規模：流通チャネル別、CAGR（2025～2032年）

• 市場概要
• 病院薬局
• オンライン薬局
• 小売薬局
• その他

チロシンキナーゼ阻害剤市場規模：地域別、CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca plc（UK）
• Roche Holding AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）
• AbbVie Inc.（USA）
• Daiichi Sankyo Company, Limited（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（GSK）（UK）
• Johnson & Johnson（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Exelixis, Inc.（USA）
• Incyte Corporation（USA）
• Ascentage Pharma（China）

結論と提言

Global Tyrosine Kinase Inhibitors Market size was valued at USD 36.9 billion in 2023 and is poised to grow from USD 39.0 billion in 2024 to USD 60.77 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The Tyrosine Kinase Inhibitors (TKIs) market is experiencing robust growth, propelled by the rising incidence of cancer and chronic illnesses that necessitate these pivotal therapies. By specifically targeting enzymes involved in cell signaling pathways, TKIs are vital in personalized medicine for treating diverse cancers like lung, breast, and leukemia. Recent advancements in molecular biology and drug development have led to the emergence of more effective, selective TKIs, enhancing patient outcomes and broadening available treatments. The market is bolstered by vigorous R&D efforts aimed at next-generation inhibitors to combat resistance and reduce side effects. However, challenges such as high costs and regulatory hurdles persist. Notably, trends like combination therapies with immunotherapies and innovative drug delivery systems are expected to further drive market expansion alongside growing global healthcare infrastructure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tyrosine Kinase Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tyrosine Kinase Inhibitors Market Segments Analysis

Global Tyrosine Kinase Inhibitors Market is segmented by Type, Application, End Users, Distribution Channel and region. Based on Type, the market is segmented into BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and Others. Based on Application, the market is segmented into Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer and Others. Based on End Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors market is primarily propelled by the alarming increase in cancer cases worldwide, especially in prevalent forms like lung cancer, breast cancer, and leukemia. Tyrosine Kinase Inhibitors (TKIs) provide targeted therapeutic strategies by disrupting specific enzymes that contribute to the proliferation of cancer cells, rendering them more effective and desirable alternatives to conventional chemotherapy methods. This rising interest in precision medicine, along with heightened public awareness and advancements in early cancer detection, is considerably widening the patient demographic that stands to benefit from the use of TKIs, further driving market growth.

Restraints in the Global Tyrosine Kinase Inhibitors Market

Although tyrosine kinase inhibitors (TKIs) offer significant clinical advantages, their high costs present a major barrier to accessibility, particularly in developing nations and for uninsured individuals. The overall expense encompasses not only the price of the medications themselves but also the necessary diagnostic tests and continual monitoring, which can put considerable pressure on healthcare systems and impede broad adoption. Financial limitations and challenges related to reimbursement may further stifle market growth, as both payers and healthcare providers look for more cost-effective treatment options. Consequently, these factors can restrict the overall reach and utilization of TKIs in various populations.

Market Trends of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors (TKIs) market is witnessing a significant trend towards the integration of combination therapies with immunotherapy, particularly alongside checkpoint inhibitors. By synergistically enhancing the immune system's tumor-targeting capabilities while simultaneously inhibiting kinase-mediated tumor growth, these innovative treatment regimens are demonstrating enhanced efficacy in early clinical trials, characterized by improved response rates and prolonged progression-free survival. As research in this area expands, the paradigm shift towards these combination approaches is poised to redefine standard oncology treatment protocols, thereby unlocking substantial growth opportunities within the TKIs market and driving an evolution in cancer care strategies globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Tyrosine Kinase Inhibitors Market Size by Type & CAGR (2025-2032)

• Market Overview
• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
• Others

Global Tyrosine Kinase Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Others

Global Tyrosine Kinase Inhibitors Market Size by End Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tyrosine Kinase Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Global Tyrosine Kinase Inhibitors Market Size & CAGR (2025-2032)

• North America (Type, Application, End Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, End Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascentage Pharma (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations